EFFECTS OF HUMAN PANCREATIC TUMOUR GROWTH HORMONE RELEASING FACTOR ON GROWTH HORMONE AND SOMATOMEDIN C LEVELS IN PATIENTS WITH IDIOPATHIC GROWTH HORMONE DEFICIENCY

JoãoL C. Borges, MarieC Gelato, AlanD Rogol, Mary Lee Vance, RobertM Macleod, Donald (Lynn) Loriaux, Jean Rivier, RobertM Blizzard, Richard Furlanetto, WilliamS Evans, DonaldL Kaiser, GeorgeR Merriam, Joachim Spiess, Wylie Vale, MichaelO Thorner

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Human pancreatic tumour growth hormone releasing factor (hpGRF-40) 10 μg/kg was administered intravenously to 6 normal young men and 12 adult patients who had presented in childhood with growth hormone (GH) deficiency (7 patients had isolated GH deficiency, 4 had multiple anterior pituitary hormone deficiencies, and 1 had Hand-Schüller-Christian [HSC] disease). hpGRF-40 administration increased serum GH concentrations in all normal subjects and in 3 of 7 patients with isolated GH deficiency and in the 1 with HSC disease; however, the mean serum GH concentration in the patients who responded was less than that of the normal subjects. Somatomedin C concentrations were increased 24 h after a single dose of hpGRF-40 in 8 of 10 patients with GH deficiency. All subjects experienced flushing in response to hpGRF-40. A patient with isolated GH deficiency received O·33 μg/kg hpGRF-40 every 3 h for 5 days. Despite the modest increase in GH in response to a subsequent dose of 10 μg/kg hpGRF-40, serum somatomedin C levels increased within 12 h from 0·06 to 0·1 U/ml and peaked at 0·36 U/ml at 72 h; in addition the patient with HSC disease, treated with hpGRF-40 daily for 5 days, demonstrated an increase in somatomedin C from 0·4 to 0·58 U/ml. The increase after hpGRF-40 in serum GH levels in this patient and the similar or greater responses in 3 of 7 patients suggest that at least some of these patients may have hypothalamic GH-releasinghormone deficiency. hpGRF-40 may be useful in distinguishing pituitary disease from hypothalamic disease. After hpGRF-40 administration serum somatomedin C levels may increase without a change in serum immunoreactive GH concentrations. Further studies are needed to determine whether hpGRF-40 is useful in promoting linear growth in children with GH deficiency.

Original languageEnglish (US)
Pages (from-to)119-124
Number of pages6
JournalThe Lancet
Volume322
Issue number8342
DOIs
StatePublished - Jul 16 1983
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor I
Growth Hormone
Pituitary Dwarfism
Serum
Hand
somatotropin releasing factor 40
Hypothalamic Diseases
Pituitary Diseases
Anterior Pituitary Hormones
Hypothalamic Hormones

ASJC Scopus subject areas

  • Medicine(all)

Cite this

EFFECTS OF HUMAN PANCREATIC TUMOUR GROWTH HORMONE RELEASING FACTOR ON GROWTH HORMONE AND SOMATOMEDIN C LEVELS IN PATIENTS WITH IDIOPATHIC GROWTH HORMONE DEFICIENCY. / Borges, JoãoL C.; Gelato, MarieC; Rogol, AlanD; Lee Vance, Mary; Macleod, RobertM; Loriaux, Donald (Lynn); Rivier, Jean; Blizzard, RobertM; Furlanetto, Richard; Evans, WilliamS; Kaiser, DonaldL; Merriam, GeorgeR; Spiess, Joachim; Vale, Wylie; Thorner, MichaelO.

In: The Lancet, Vol. 322, No. 8342, 16.07.1983, p. 119-124.

Research output: Contribution to journalArticle

Borges, JC, Gelato, M, Rogol, A, Lee Vance, M, Macleod, R, Loriaux, DL, Rivier, J, Blizzard, R, Furlanetto, R, Evans, W, Kaiser, D, Merriam, G, Spiess, J, Vale, W & Thorner, M 1983, 'EFFECTS OF HUMAN PANCREATIC TUMOUR GROWTH HORMONE RELEASING FACTOR ON GROWTH HORMONE AND SOMATOMEDIN C LEVELS IN PATIENTS WITH IDIOPATHIC GROWTH HORMONE DEFICIENCY', The Lancet, vol. 322, no. 8342, pp. 119-124. https://doi.org/10.1016/S0140-6736(83)90113-7
Borges, JoãoL C. ; Gelato, MarieC ; Rogol, AlanD ; Lee Vance, Mary ; Macleod, RobertM ; Loriaux, Donald (Lynn) ; Rivier, Jean ; Blizzard, RobertM ; Furlanetto, Richard ; Evans, WilliamS ; Kaiser, DonaldL ; Merriam, GeorgeR ; Spiess, Joachim ; Vale, Wylie ; Thorner, MichaelO. / EFFECTS OF HUMAN PANCREATIC TUMOUR GROWTH HORMONE RELEASING FACTOR ON GROWTH HORMONE AND SOMATOMEDIN C LEVELS IN PATIENTS WITH IDIOPATHIC GROWTH HORMONE DEFICIENCY. In: The Lancet. 1983 ; Vol. 322, No. 8342. pp. 119-124.
@article{9ad9e0f69c6a451785f6df6ff91e9d8d,
title = "EFFECTS OF HUMAN PANCREATIC TUMOUR GROWTH HORMONE RELEASING FACTOR ON GROWTH HORMONE AND SOMATOMEDIN C LEVELS IN PATIENTS WITH IDIOPATHIC GROWTH HORMONE DEFICIENCY",
abstract = "Human pancreatic tumour growth hormone releasing factor (hpGRF-40) 10 μg/kg was administered intravenously to 6 normal young men and 12 adult patients who had presented in childhood with growth hormone (GH) deficiency (7 patients had isolated GH deficiency, 4 had multiple anterior pituitary hormone deficiencies, and 1 had Hand-Sch{\"u}ller-Christian [HSC] disease). hpGRF-40 administration increased serum GH concentrations in all normal subjects and in 3 of 7 patients with isolated GH deficiency and in the 1 with HSC disease; however, the mean serum GH concentration in the patients who responded was less than that of the normal subjects. Somatomedin C concentrations were increased 24 h after a single dose of hpGRF-40 in 8 of 10 patients with GH deficiency. All subjects experienced flushing in response to hpGRF-40. A patient with isolated GH deficiency received O·33 μg/kg hpGRF-40 every 3 h for 5 days. Despite the modest increase in GH in response to a subsequent dose of 10 μg/kg hpGRF-40, serum somatomedin C levels increased within 12 h from 0·06 to 0·1 U/ml and peaked at 0·36 U/ml at 72 h; in addition the patient with HSC disease, treated with hpGRF-40 daily for 5 days, demonstrated an increase in somatomedin C from 0·4 to 0·58 U/ml. The increase after hpGRF-40 in serum GH levels in this patient and the similar or greater responses in 3 of 7 patients suggest that at least some of these patients may have hypothalamic GH-releasinghormone deficiency. hpGRF-40 may be useful in distinguishing pituitary disease from hypothalamic disease. After hpGRF-40 administration serum somatomedin C levels may increase without a change in serum immunoreactive GH concentrations. Further studies are needed to determine whether hpGRF-40 is useful in promoting linear growth in children with GH deficiency.",
author = "Borges, {Jo{\~a}oL C.} and MarieC Gelato and AlanD Rogol and {Lee Vance}, Mary and RobertM Macleod and Loriaux, {Donald (Lynn)} and Jean Rivier and RobertM Blizzard and Richard Furlanetto and WilliamS Evans and DonaldL Kaiser and GeorgeR Merriam and Joachim Spiess and Wylie Vale and MichaelO Thorner",
year = "1983",
month = "7",
day = "16",
doi = "10.1016/S0140-6736(83)90113-7",
language = "English (US)",
volume = "322",
pages = "119--124",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8342",

}

TY - JOUR

T1 - EFFECTS OF HUMAN PANCREATIC TUMOUR GROWTH HORMONE RELEASING FACTOR ON GROWTH HORMONE AND SOMATOMEDIN C LEVELS IN PATIENTS WITH IDIOPATHIC GROWTH HORMONE DEFICIENCY

AU - Borges, JoãoL C.

AU - Gelato, MarieC

AU - Rogol, AlanD

AU - Lee Vance, Mary

AU - Macleod, RobertM

AU - Loriaux, Donald (Lynn)

AU - Rivier, Jean

AU - Blizzard, RobertM

AU - Furlanetto, Richard

AU - Evans, WilliamS

AU - Kaiser, DonaldL

AU - Merriam, GeorgeR

AU - Spiess, Joachim

AU - Vale, Wylie

AU - Thorner, MichaelO

PY - 1983/7/16

Y1 - 1983/7/16

N2 - Human pancreatic tumour growth hormone releasing factor (hpGRF-40) 10 μg/kg was administered intravenously to 6 normal young men and 12 adult patients who had presented in childhood with growth hormone (GH) deficiency (7 patients had isolated GH deficiency, 4 had multiple anterior pituitary hormone deficiencies, and 1 had Hand-Schüller-Christian [HSC] disease). hpGRF-40 administration increased serum GH concentrations in all normal subjects and in 3 of 7 patients with isolated GH deficiency and in the 1 with HSC disease; however, the mean serum GH concentration in the patients who responded was less than that of the normal subjects. Somatomedin C concentrations were increased 24 h after a single dose of hpGRF-40 in 8 of 10 patients with GH deficiency. All subjects experienced flushing in response to hpGRF-40. A patient with isolated GH deficiency received O·33 μg/kg hpGRF-40 every 3 h for 5 days. Despite the modest increase in GH in response to a subsequent dose of 10 μg/kg hpGRF-40, serum somatomedin C levels increased within 12 h from 0·06 to 0·1 U/ml and peaked at 0·36 U/ml at 72 h; in addition the patient with HSC disease, treated with hpGRF-40 daily for 5 days, demonstrated an increase in somatomedin C from 0·4 to 0·58 U/ml. The increase after hpGRF-40 in serum GH levels in this patient and the similar or greater responses in 3 of 7 patients suggest that at least some of these patients may have hypothalamic GH-releasinghormone deficiency. hpGRF-40 may be useful in distinguishing pituitary disease from hypothalamic disease. After hpGRF-40 administration serum somatomedin C levels may increase without a change in serum immunoreactive GH concentrations. Further studies are needed to determine whether hpGRF-40 is useful in promoting linear growth in children with GH deficiency.

AB - Human pancreatic tumour growth hormone releasing factor (hpGRF-40) 10 μg/kg was administered intravenously to 6 normal young men and 12 adult patients who had presented in childhood with growth hormone (GH) deficiency (7 patients had isolated GH deficiency, 4 had multiple anterior pituitary hormone deficiencies, and 1 had Hand-Schüller-Christian [HSC] disease). hpGRF-40 administration increased serum GH concentrations in all normal subjects and in 3 of 7 patients with isolated GH deficiency and in the 1 with HSC disease; however, the mean serum GH concentration in the patients who responded was less than that of the normal subjects. Somatomedin C concentrations were increased 24 h after a single dose of hpGRF-40 in 8 of 10 patients with GH deficiency. All subjects experienced flushing in response to hpGRF-40. A patient with isolated GH deficiency received O·33 μg/kg hpGRF-40 every 3 h for 5 days. Despite the modest increase in GH in response to a subsequent dose of 10 μg/kg hpGRF-40, serum somatomedin C levels increased within 12 h from 0·06 to 0·1 U/ml and peaked at 0·36 U/ml at 72 h; in addition the patient with HSC disease, treated with hpGRF-40 daily for 5 days, demonstrated an increase in somatomedin C from 0·4 to 0·58 U/ml. The increase after hpGRF-40 in serum GH levels in this patient and the similar or greater responses in 3 of 7 patients suggest that at least some of these patients may have hypothalamic GH-releasinghormone deficiency. hpGRF-40 may be useful in distinguishing pituitary disease from hypothalamic disease. After hpGRF-40 administration serum somatomedin C levels may increase without a change in serum immunoreactive GH concentrations. Further studies are needed to determine whether hpGRF-40 is useful in promoting linear growth in children with GH deficiency.

UR - http://www.scopus.com/inward/record.url?scp=0020520455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020520455&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(83)90113-7

DO - 10.1016/S0140-6736(83)90113-7

M3 - Article

C2 - 6134978

AN - SCOPUS:0020520455

VL - 322

SP - 119

EP - 124

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8342

ER -